Eyedaptic, founded in 2016 and headquartered in the United States, is making strides in the wearable device sector with its focus on improving the quality of life for individuals affected by age-related macular degeneration (AMD). Their product, AdaptiVu, offers Simulated Natural Vision Eyewear for AMD Sufferers, leveraging innovative proprietary software to enhance vision in a natural and non-invasive way.
This technology has been developed in collaboration with leading ophthalmologists and other specialists, ensuring its effectiveness and user-friendly design. The glasses are battery-powered and FDA exempt, simplifying the path to market penetration.
Most recently, Eyedaptic secured a $700.00K investment through an Equity Crowdfunding round in March 2023. This capital infusion is a promising signal of investor confidence, and it positions the company to continue refining its product and expanding its market reach.